Zilebesiran
Highest phase reached
Phase 2
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Oligonucleotide
- Drug name
- Zilebesiran
- [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2- acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17- triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methyl all-P-ambo-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'- fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl- (3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')- 2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyl-3'-adenylate, duplex with all-P-ambo-2'-O-methyl-P-thioadenylyl-(5'→3')-2'-O-methyl-P-thioguanylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl- (5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'- fluorouridylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→2')-1- de-β-D-ribofuranosyl-1-[(2S)-2,3-dihydroxypropyl]-5-methyluridylyl-(3'→3')-2'-O-methylcytidylyl-(5'→3')-2'- O-methyladenylyl-(5'→3')-2'-O-methyl-P-thiouridylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thioguanylyl-(5'→3')-2'-O-methyluridine
- 2s 4r 1 1 2 acetamido 2 deoxy β d galactopyranosyl oxy 16 16 bis 3 3 5 2 acetamido 2 deoxy β d galactopyranosyl oxy pentanamido propyl amino 3 oxopropoxy methyl 5 11 18 trioxo 14 oxa 6 10 17 triazanonacosan 29 oyl 4 hydroxypyrrolidin 2 yl methyl all p ambo 2 o methyl p thioguanylyl 3 5 2 o methyl p thiouridylyl 3 5 2 o methylcytidylyl 3 5 2 o methyladenylyl 3 5 2 o methyluridylyl 3 5 2 o methylcytidylyl 3 5 2 deoxy 2 fluorocytidylyl 3 5 2 o methyladenylyl 3 5 2 deoxy 2 fluorocytidylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 o methyluridylyl 3 5 2 o methylguanylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 o methyluridylyl 3 5 2 o methyladenylyl 3 5 2 o methylcytidylyl 3 5 2 o methyl 3 adenylate duplex with all p ambo 2 o methyl p thioadenylyl 5 3 2 o methyl p thioguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methylguanylyl 5 3 2 o methyluridylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluoroguanylyl 5 3 2 o methylguanylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methylguanylyl 5 3 2 o methyluridylyl 5 3 2 o methyluridylyl 5 3 2 o methyladenylyl 5 3 2 o methylcytidylyl 5 3 2 o methyluridylyl 5 3 2 o methylcytidylyl 5 2 1 de β d ribofuranosyl 1 2s 2 3 dihydroxypropyl 5 methyluridylyl 3 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methyl p thiouridylyl 5 3 2 deoxy 2 fluoro p thioguanylyl 5 3 2 o methyluridine
- ad 85481
- AD-85481
- aln 85481
- aln agt01
- ALN-85481
- ALN-AGT01
- rna gm sp um sp cm am um cm 2 deoxy 2 fluoro c am 2 deoxy 2 fluoro c 2 deoxy 2 fluoro a 2 deoxy 2 fluoro a um gm am gm am gm um am cm am 3 2s 4r 1 29 2 acetylamino 2 deoxy β d galactopyranosyl oxy 14 14 bis 3 3 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino propyl amino 3 oxopropoxy methyl 1 12 19 25 tetraoxo 16 oxa 13 20 24 triazanonacos 1 yl 4 hydroxy 2 pyrrolidinyl methyl hydrogen phosphate complex with rna um sp 2 deoxy 2 fluoro g sp um am cm 3 3 1 de β d ribofuranosyl 1 2s 2 3 dihydroxypropyl m5u 2 5 cm um cm am um um gm 2 deoxy 2 fluoro u gm 2 deoxy 2 fluoro g am um gm am cm sp gm sp am 1 1
- RNA, (Gm-sp-Um-sp-Cm-Am-Um-Cm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)A-Um-Gm-Am-Gm-Am-Gm-Um-Am-Cm-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]- 4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)G-sp-Um-Am-Cm-(3'→3')-[1-de-β-D-ribofuranosyl-1-[(2S)-2,3-dihydroxypropyl]]m5U-(2'→5')-Cm-Um-Cm-Am-Um-Um-Gm-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)G-Am-Um-Gm-Am-Cm-sp-Gm-sp-Am) (1:1)
- zilebesiran
- Zilebesiran
- zilebesiran [INN]
- ZILEBESIRAN [USAN]
- zilebesiran inn
- zilebesiran usan
- CAS registry numbers
- 2380166-33-4
- ChEMBL ID
- CHEMBL5095298
- FDA ingredient codes (UNII)
- E422BH4BRK
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Hypertension
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- HP_0000822
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 2
- NCT03934307
- NCT05103332
- NCT06423352
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- (3'-5') G=U=C-A-U-C-C-A-C-A-A-U-G-A-G-A-G-U=A-C-A-R1 (5'-3') A=G=C-A-G-U-A-G-G-U-G-U-U-A-C-U-C-U1-C-A-U=G=U1
Related records
Trials (8)
- A Study to Evaluate ALN-AGT01 in Patients With Hypertension
- A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers
- A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
- A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
In development for (1)
- Hypertensive disorder Phase 2